“…The potential advantages of irreversible inhibitors include low dose requirements and reduced off-target toxicity. , Furthermore, this irreversible inhibitor does not covalently bind to the protein, which should significantly reduce the potential for an immune response. To fully explore the structure–activity relationship (SAR) around the PF-04859989 scaffold, several synthetic approaches were developed (see Scheme ); detailed descriptions of these methods have recently been disclosed. , In general, the synthesis of 7 and its analogues requires access to α-amino acids or α-amino esters, which undergo reductive cyclization to afford 3-amino-1-hydroxy-3,4-dihydroquinolin-2(1 H )-ones. In the case of 7 itself, direct catalytic reductive cyclization using Pt/C and H 2 (method A) provided clean conversion to the desired product without competitive over-reduction to the corresponding lactam.…”